← Back to Search

[18F]F-AraG PET Scan Reliability for Lung Cancer

Phase 2
Recruiting
Led By Muhammad Furqan, M.D.
Research Sponsored by CellSight Technologies, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients (>18 years old) with a histologically confirmed NSCLC and a candidate to receive immunotherapy as monotherapy or as combination therapy for advanced/metastatic disease
Measurable disease
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 7 days
Awards & highlights
No Placebo-Only Group

Summary

This trial studies if PET scans of advanced lung cancer patients are reliable when taken within 7 days of each other. Patients receive 2 scans & care providers are aware of study.

Who is the study for?
This trial is for adults over 18 with advanced non-small cell lung cancer (NSCLC) who are candidates for immunotherapy. They should have measurable disease and be in a relatively stable condition, as indicated by an ECOG performance status of 0 to 2. Pregnant or nursing women, individuals with severe claustrophobia, or those with serious health issues that could interfere with the study cannot participate.
What is being tested?
[18F]F-AraG PET imaging is being tested to see how consistent it is when used twice within a week on patients with advanced NSCLC. The goal is to measure how much [18F]F-AraG builds up in tumors and immune system tissues before treatment starts. This single-site pilot trial involves two scans without any blinding.
What are the potential side effects?
As this trial focuses on PET/CT imaging using [18F]F-AraG, side effects may include discomfort from lying still during the scan and potential reactions to the tracer like rash or itching. There's also exposure to radiation similar to other medical imaging procedures.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am over 18 with confirmed NSCLC and can receive immunotherapy.
Select...
My cancer can be measured by tests.
Select...
I can take care of myself and am up and about more than half of my waking hours.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~7 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 7 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
[18F]F-AraG Test - Re Test

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Advanced non small cell lung cancer (NSCLC) patientsExperimental Treatment1 Intervention
Patients will undergo two \[18F\]F AraG PET/CT scans within 7 days of each other prior to receiving treatment

Find a Location

Who is running the clinical trial?

CellSight Technologies, Inc.Lead Sponsor
17 Previous Clinical Trials
313 Total Patients Enrolled
University of Iowa Hospitals & ClinicsUNKNOWN
University of IowaOTHER
471 Previous Clinical Trials
894,651 Total Patients Enrolled
Muhammad Furqan, M.D.Principal InvestigatorHolden Comprehensive Cancer Center
1 Previous Clinical Trials
20 Total Patients Enrolled
~4 spots leftby Oct 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top